BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25325301)

  • 1. Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.
    Assouline SE; Chang J; Cheson BD; Rifkin R; Hamburg S; Reyes R; Hui AM; Yu J; Gupta N; Di Bacco A; Shou Y; Martin P
    Blood Cancer J; 2014 Oct; 4(10):e251. PubMed ID: 25325301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
    Kumar SK; Bensinger WI; Zimmerman TM; Reeder CB; Berenson JR; Berg D; Hui AM; Gupta N; Di Bacco A; Yu J; Shou Y; Niesvizky R
    Blood; 2014 Aug; 124(7):1047-55. PubMed ID: 24904120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
    Sanchorawala V; Palladini G; Kukreti V; Zonder JA; Cohen AD; Seldin DC; Dispenzieri A; Jaccard A; Schönland SO; Berg D; Yang H; Gupta N; Hui AM; Comenzo RL; Merlini G
    Blood; 2017 Aug; 130(5):597-605. PubMed ID: 28550039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
    Richardson PG; Baz R; Wang M; Jakubowiak AJ; Laubach JP; Harvey RD; Talpaz M; Berg D; Liu G; Yu J; Gupta N; Di Bacco A; Hui AM; Lonial S
    Blood; 2014 Aug; 124(7):1038-46. PubMed ID: 24920586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
    Smith DC; Kalebic T; Infante JR; Siu LL; Sullivan D; Vlahovic G; Kauh JS; Gao F; Berger AJ; Tirrell S; Gupta N; Di Bacco A; Berg D; Liu G; Lin J; Hui AM; Thompson JA
    Invest New Drugs; 2015 Jun; 33(3):652-63. PubMed ID: 25777468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
    Suzuki K; Handa H; Chou T; Ishizawa K; Takubo T; Kase Y
    Int J Hematol; 2017 Apr; 105(4):445-452. PubMed ID: 28000099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
    Gupta N; Labotka R; Liu G; Hui AM; Venkatakrishnan K
    Invest New Drugs; 2016 Jun; 34(3):338-46. PubMed ID: 27039387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
    Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
    Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study.
    Liu A; Yu H; Hou R; Zhu Z; Zhuang JL; Bao L; Li Z; Liu L; Hua L; Ma Y; Gao D; Jin A; Suo X; Yang W; Bai Y; Fu R; Zheng D; Chen W
    Cancer Med; 2024 May; 13(9):e7177. PubMed ID: 38686615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.
    Gupta N; Yang H; Hanley MJ; Zhang S; Liu R; Kumar S; Richardson PG; Skacel T; Venkatakrishnan K
    Target Oncol; 2017 Oct; 12(5):643-654. PubMed ID: 28803351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.
    Kersten MJ; Amaador K; Minnema MC; Vos JMI; Nasserinejad K; Kap M; Kastritis E; Gavriatopoulou M; Kraan W; Chamuleau MED; Deeren D; Tick LW; Doorduijn JK; Offner F; Böhmer LH; Liu RD; Pals ST; Dimopoulos MA
    J Clin Oncol; 2022 Jan; 40(1):40-51. PubMed ID: 34388022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
    Li J; Bao L; Xia Z; Wang S; Zhou X; Ding K; Zhang W; Yang W; Li B; Fu C; Chen B; Hua L; Wang L; Luo J; Yang Y; Xu T; Wang W; Huang Y; Wu G; Liu P
    Ann Hematol; 2020 Nov; 99(11):2589-2598. PubMed ID: 32892275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
    Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
    J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Gastrointestinal Toxicities From Ixazomib: Tips to Curb Nausea, Vomiting, Diarrhea, and Constipation.
    Hall KH
    Oncology (Williston Park); 2019 Mar; 33(3):89-90. PubMed ID: 30866030
    [No Abstract]   [Full Text] [Related]  

  • 16. A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
    Hanley MJ; Gupta N; Venkatakrishnan K; Bessudo A; Sharma S; O'Neil BH; Wang B; van de Velde H; Nemunaitis J
    J Clin Pharmacol; 2018 Jan; 58(1):114-121. PubMed ID: 28783865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
    Gupta N; Goh YT; Min CK; Lee JH; Kim K; Wong RS; Chim CS; Hanley MJ; Yang H; Venkatakrishnan K; Hui AM; Esseltine DL; Chng WJ
    J Hematol Oncol; 2015 Sep; 8():103. PubMed ID: 26337806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
    Moreau P; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Simpson DR; Gimsing P; Palumbo A; Garderet L; Cavo M; Kumar S; Touzeau C; Buadi FK; Laubach JP; Berg DT; Lin J; Di Bacco A; Hui AM; van de Velde H; Richardson PG;
    N Engl J Med; 2016 Apr; 374(17):1621-34. PubMed ID: 27119237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide, rituximab (R
    Hill BT; Chen Y; Jagadeesh D; Dean R; Koc O; Boughan K; Cooper B; Pohlman B; Caimi P; Smith MR
    Leuk Lymphoma; 2024 Jun; 65(6):768-773. PubMed ID: 38456694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
    Rinnerthaler G; Gampenrieder SP; Petzer A; Burgstaller S; Fuchs D; Rossmann D; Balic M; Egle D; Rumpold H; Singer CF; Bartsch R; Petru E; Melchardt T; Ulmer H; Mlineritsch B; Greil R
    BMC Cancer; 2018 Nov; 18(1):1074. PubMed ID: 30400780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.